DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$10.63
+0.29 (+2.80%)
Open$10.67
Previous Close$10.34
Day High$10.79
Day Low$10.31
52W High$17.25
52W Low$6.16
Volume—
Avg Volume410.9K
Market Cap668.37M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+454.6% upside
Current
$10.63
$10.63
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |
| Rev Growth | +7.4% | +3.0% | +5.7% |
| Debt/Equity | 0.91 | 1.04 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |